Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 11;229(1):19–29. doi: 10.1093/infdis/jiad220

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 1. — Study schematic: cohort 2. Ad26, adenovector 26; AE, adverse event; HD, high dose; LD, low dose; preF, prefusion conformation-stabilized RSV F protein; RSV, respiratory syncytial virus; SAE, serious adverse event; vp, viral particle. ^aAd26.RSV.preF. ^bInjections given in opposite arms. ^cA combination injection of Ad26.RSV.preF and recombinant RSV preF protein at the specified dosages. ^dRecombinant RSV preF protein. ^eCohort 1 received an additional dose at day 365.